Evotec SE ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $824.9M-4.6% YoYTTM through 31 Dec 2024
Net Income -$203MTTM through 31 Dec 2024
Free Cash Flow -$103.3MTTM through 31 Dec 2024
Margins
| Current | |
|---|---|
| Gross Margin | 14.5% |
| Operating Margin | -17.9% |
| Net Margin | -24.6% |
Returns
-12.7%ROE
-6.0%ROA
Balance Sheet Health
Debt / Equity0.48x
Current Ratio1.68x
Net Debt-$88.9Mnet cash position
Cash & Equivalents$306.4M
Quality Metrics
Piotroski F-Score4 / 9
FCF Margin-12.5%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2024: $797M
Diluted EPSFY2024: $-1.11
Dividend
No dividend
Capital Allocation
Capex Intensity14.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Discovery & Preclinical Development (D&PD) | $528.9M | -13.5% | View detailsEarly drug discovery market softness and temporary decline in BMS collaboration revenues impacted performance, with recovery expected as early as 2026. |
| Just – Evotec Biologics (JEB) | $259.4M |
Financials converted at 0.9610 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.